tetano
Editor, Senior Moderator
Swiss Med Wkly. 2014 May 20;144:w13940. doi: 10.4414/smw.2014.13940. eCollection 2014.
Vaccine adjuvants - understanding molecular mechanisms to improve vaccines.
Egli A1, Santer D2, Barakat K3, Zand M4, Levin A5, Vollmer M6, Weisser M7, Khanna N8, Kumar D9, Tyrrell L5, Houghton M5, Battegay M7, O'Shea D10.
Author information
Abstract
Infectious pathogens are responsible for high utilisation of healthcare resources globally. Attributable morbidity and mortality remains exceptionally high. Vaccines offer the potential to prime a pathogen-specific immune response and subsequently reduce disease burden. Routine vaccination has fundamentally altered the natural history of many frequently observed and serious infections. Vaccination is also recommended for persons at increased risk of severe vaccine-preventable disease. Many current nonadjuvanted vaccines are poorly effective in the elderly and immunocompromised populations, resulting in nonprotective postvaccine antibody titres, which serve as surrogate markers for protection. The vaccine-induced immune response is influenced by: (i.) vaccine factors i.e., type and composition of the antigen(s), (ii.) host factors i.e., genetic differences in immune-signalling or senescence, and (iii.) external factors such as immunosuppressive drugs or diseases. Adjuvanted vaccines offer the potential to compensate for a lack of stimulation and improve pathogen-specific protection. In this review we use influenza vaccine as a model in a discussion of the different mechanisms of action of the available adjuvants. In addition, we will appraise new approaches using "vaccine-omics" to discover novel types of adjuvants.
PMID:
24844935
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/24844935
Vaccine adjuvants - understanding molecular mechanisms to improve vaccines.
Egli A1, Santer D2, Barakat K3, Zand M4, Levin A5, Vollmer M6, Weisser M7, Khanna N8, Kumar D9, Tyrrell L5, Houghton M5, Battegay M7, O'Shea D10.
Author information
Abstract
Infectious pathogens are responsible for high utilisation of healthcare resources globally. Attributable morbidity and mortality remains exceptionally high. Vaccines offer the potential to prime a pathogen-specific immune response and subsequently reduce disease burden. Routine vaccination has fundamentally altered the natural history of many frequently observed and serious infections. Vaccination is also recommended for persons at increased risk of severe vaccine-preventable disease. Many current nonadjuvanted vaccines are poorly effective in the elderly and immunocompromised populations, resulting in nonprotective postvaccine antibody titres, which serve as surrogate markers for protection. The vaccine-induced immune response is influenced by: (i.) vaccine factors i.e., type and composition of the antigen(s), (ii.) host factors i.e., genetic differences in immune-signalling or senescence, and (iii.) external factors such as immunosuppressive drugs or diseases. Adjuvanted vaccines offer the potential to compensate for a lack of stimulation and improve pathogen-specific protection. In this review we use influenza vaccine as a model in a discussion of the different mechanisms of action of the available adjuvants. In addition, we will appraise new approaches using "vaccine-omics" to discover novel types of adjuvants.
PMID:
24844935
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/24844935